Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme to Sell Third Wave s Colorectal Cancer PGx Test in North America

NEW YORK, Oct. 27 (GenomeWeb News) - Genzyme Genetics will sell Third Wave's Invader UGT1A1 molecular assay to identify colorectal cancer patients who could be considered for, or currently undergoing, chemotherapy with Camptosar, the companies said today.

Besides launching the test in North America, Genzyme will begin a "direct education program" aimed at oncologists and pathologists in that market the companies said.

The Invader UGT1A1 molecular assay identifies patients who may be at increased risk for adverse reactions to Camptosar, developed by Pharmacia, by detecting variations in the UGT1A1 gene that have been associated with that risk.


A clinical study indicated that patients with one of these variations have a greater than nine-fold increased risk of experiencing toxicity from Camptosar than patients without the variation, the companies said. As such, Camptosar's labeling was recently updated to include dosing recommendations based on a patient's UGT1A1 status.

Wave said it will make the assay available to its current customers.


Financial details were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more